Erytech

Closed

Helping patients live longer, better.

Public · Lyon, France · Founded 2004 · $274.6M raised

Headquarters
Lyon
Employees
51–200
Founded
2004
Business Model
B2B
Total Funding
$274.6M
Last Round
$144.0M Private EquityNov 2017
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

ERYTECH is a clinical-stage biopharmaceutical company that developed innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Founded in Lyon, France in 2004, the company focused on encapsulating therapeutic agents inside red blood cells to reduce toxicity and improve efficacy. ERYTECH was listed on the Nasdaq Capital Market and Euronext Paris. The company later merged with PHERECYDES to form PHAXIAM Therapeutics, which subsequently entered judicial restructuring in 2025.

Summary

Erytech is a Biotech company based in Lyon, France, founded in 2004. It has raised $274.6M in total across 4 rounds, most recently a $144.0M Private Equity round in Nov 2017.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Debt FinancingDebt FinancingJun 2020

Sign up to see all 6 events

Funding: Private Equity. Amounts, valuations, and investors where available.

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Erytech on Indexed.vc
<a href="https://indexed.vc/companies/erytech-pharma-sa"><img src="https://indexed.vc/api/badge/company/erytech-pharma-sa" alt="Erytech on Indexed.vc" width="260" height="76" /></a>